Genelabs Grants Non-Exclusive License for DNA Technology

February 3, 2003

1 Min Read
Supply Side Supplement Journal logo in a gray background | Supply Side Supplement Journal


Genelabs Grants Non-Exclusive License for DNA Technology

REDWOOD CITY, Calif.--Genelabs Technologies Inc. announced thatit granted a non-exclusive license for its LADA technology to an unnamed geneticanalysis tool company. In exchange for the license, Genelabs will receive anup-front fee, annual fees and royalties on licensed products and services.

Genelabs' LADA technology, known as Linker-Aided DNA Amplificationtechnology, is covered by U.S. patent #6,107,023, as well as correspondinginternational patents. The patent, titled "DNA Amplification andSubtraction Techniques," covers a method of amplifying nucleic acids byattaching DNA linkers of known sequence to the ends of DNA sequences targetedfor amplification.

Genelabs (www.genelabs.com) plans toenter into additional licensing agreements in the future.

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like